Results 71 to 80 of about 929 (159)

Issue Information

open access: yes
Rheumatology &Autoimmunity, Volume 6, Issue 1, March 2026.
wiley   +1 more source

Understanding Myelodysplasia and Inflammation Through the Lense of VEXAS Syndrome: A Review

open access: yesCells
VEXAS syndrome, a monogenic X-linked disorder resulting from mutations in the UBA1 gene, has emerged as a key model for unraveling the links between systemic inflammatory or autoimmune diseases (SIAD) and myelodysplastic syndromes (MD).
Louis Wolff   +4 more
doaj   +1 more source

Unveiling VEXAS Syndrome: When Skin Manifestations and Monoclonal Gammopathy Precede Myeloid‐Lineage Hematologic Abnormality

open access: yesACR Open Rheumatology
VEXAS (vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic) syndrome is a rare disorder caused by somatic UBA1 gene mutations, characterized by autoinflammation and hematologic abnormalities, particularly affecting myeloid‐lineage progenitors ...
Laura Di Centa   +4 more
doaj   +1 more source

VEXAS syndrome in a Moroccan patient: the story of a two-year diagnostic lag

open access: yesEuropean Journal of Case Reports in Internal Medicine
Background: VEXAS syndrome, also known as vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome, is a newly identified genetic condition characterised by a combination of autoinflammatory symptoms and myeloid dysplasia.
Abire Allaoui   +6 more
doaj   +1 more source

DP059 | AN ITALIAN CARTOGRAPHY OF VEXAS-RELATED THROMBOSIS: A 218 PATIENT-YEARS ANALYSIS

open access: yesHaematologica
While thrombotic events (TE) occur in up to 40% of VEXAS cases, a scarcity of data exists on its clinical-genomic associations or anti-coagulation strategies.
G. Ranucci   +33 more
doaj  

VEXAS Syndrome and Alzheimer’s Disease—Are There Connections?

open access: yesBrain Sciences
VEXAS syndrome and Alzheimer’s disease (AD), though distinct in clinical manifestations, share overlapping pathophysiological mechanisms, including systemic inflammation, protein misfolding, and vascular dysfunction.
Aleksandra Sowa   +4 more
doaj   +1 more source

Efficacy and safety profile of biotechnological agents and Janus kinase inhibitors in VEXAS syndrome: data from the international AIDA Network VEXAS registry

open access: yesFrontiers in Pharmacology
BackgroundVEXAS syndrome, a recently identified systemic autoinflammatory disorder, poses new diagnostic and management challenges. Based on experience with other autoinflammatory diseases, anti-interleukin (IL)-1, anti-IL-6, anti-tumor necrosis factor ...
Antonio Vitale   +83 more
doaj   +1 more source

A vexing case of a 73‐year‐old man with fevers, orbital cellulitis, and asymptomatic interstitial lung disease

open access: yesRespirology Case Reports
VEXAS (Vacuoles, E1 enzyme, X‐linked, Autoinflammatory, Somatic) syndrome is a rare and recently identified disease resulting from a somatic mutation in the X‐linked UBA1 gene in cells of myeloid lineage.
Sushil Agwan   +5 more
doaj   +1 more source

VEXAS Syndrome: A Comprehensive Review of Clinical Mimickers and Differential Diagnosis at the Rheumatology–Haematology Interface

open access: yesJournal of Education, Health and Sport
VEXAS syndrome is a newly described autoimmune disorder in adults caused by a somatic mutation in the UBA1 gene located on the X chromosome, occurring almost exclusively in older men.
Hanna Aleksandrowicz   +5 more
doaj   +1 more source

PO60 | VEXAS SYNDROME AS A NEW SEVERE THROMBOPHILIC CLONAL CONDITION: A SINGLE CENTRE EXPERIENCE

open access: yesBleeding, Thrombosis and Vascular Biology
Introduction. VEXAS syndrome is an autoinflammatory condition first described in 2020. Reported VTE incidence is from 35 to 57%. Little is known about the best anticoagulant duration, intensity and risk of recurrence. Aim To describe the incidence of VTE
Chiara Ambaglio
doaj  

Home - About - Disclaimer - Privacy